Render Target: STATIC
Render Timestamp: 2025-02-07T11:04:32.991Z
Commit: 1bba917eefc12d62e72a522121e2774ffbd0ee36
XML generation date: 2024-09-30 01:54:18.472
Product last modified at: 2025-01-01T09:05:55.749Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CIP2A (D1M3H) Rabbit mAb #14805

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 90
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CIP2A (D1M3H) Rabbit mAb recognizes endogenous levels of total CIP2A protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val342 of human CIP2A protein.

    Background

    Protein phosphatase 2A (PP2A) is a trimeric protein phosphatase and tumor suppressor that regulates the phosphorylation status of a wide variety of phosphoproteins. PP2A targets include many that play a role in the maintenance and progression of cancer (1). The cancerous inhibitor of protein phosphatase 2A (CIP2A) is a single pass membrane protein that binds the PP2A catalytic subunit to inhibit PP2A phosphatase activity (2). CIP2A is normally expressed at low levels in normal cells and tissues, but is elevated in human malignancies where it is thought to be oncogenic. Research studies demonstrate aberrant CIP2A expression in multiple tumor types, including those derived from the head and neck, liver, colon, lung, osteosarcoma, pancreatic, breast, and myeloid cancers (reviewed in 3). This evidence suggests that CIP2A interacts with many proteins that may play a role in cancer maintenance and progression (3). Additional studies indicate that CIP2A inhibits PP2A-mediated dephosphorylation of the proto-oncogene Myc at Ser64, which stabilizes and prevents proteolytic degradation of the Myc transcription factor (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.